N-[2-[P-溴苯丙烯盐基氨基]乙基]-5-异喹啉磺酰胺
中文名称 | N-[2-[P-溴苯丙烯盐基氨基]乙基]-5-异喹啉磺酰胺 |
---|---|
中文同义词 | N-[2-[[3-(4-溴苯基)-2-丙烯-1-基]氨基]乙基]-5-异喹啉磺酰胺;N-[2-[P-溴苯丙烯盐基氨基]乙基]-5-异喹啉磺酰胺;N-[2-[P-溴苯丙烯盐基氨基]乙基]-5-异喹啉磺酰胺二盐酸盐(H-89二盐酸盐);N - [2 - (P溴肉桂氨基酸乙基] -5 - 异喹啉磺胺类药物;H-89二盐酸盐, 一种高效的选择性PKA抑制剂;(BASE),H-89 & H-89 2HCL游离,盐酸盐;化合物 H-89 |
英文名称 | N-(2-[P-BROMOCINNAMYLAMINO]ETHYL)-5-ISOQUINOLINESULFONAMIDE HYDROCHLORIDE |
英文同义词 | H-89;H-89 DIHYDROCHLORIDE;H-89 HYDROCHLORIDE;N-[2-(P-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE;N-[2-(P-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE 2HCL;N-[2-(P-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE, DIHYDROCHLORIDE;N-(2-[P-BROMOCINNAMYLAMINO]ETHYL)-5-ISOQUINOLINESULFONAMIDE HYDROCHLORIDE;N-[2-[P-BROMOCINNAMYLAMINO]-ETHYL]-5-ISOQUINOLINESULFONMIDE |
CAS号 | 127243-85-0 |
分子式 | C20H20BrN3O2S |
分子量 | 446.36 |
EINECS号 | |
相关类别 | 定制化学品;医药中间体;Inhibitor;Protein Kinase Inhibitors and Activators |
Mol文件 | 127243-85-0.mol |
结构式 |
N-[2-[P-溴苯丙烯盐基氨基]乙基]-5-异喹啉磺酰胺 性质
熔点 | 195-200°C |
---|---|
沸点 | 639.7±65.0 °C(Predicted) |
密度 | 1.436 |
储存条件 | 2-8°C |
溶解度 | H2O: ≥10 mg/mL |
形态 | 粉末 |
酸度系数(pKa) | 10.43±0.50(Predicted) |
颜色 | 米白色 |
稳定性 | 自购买之日起,稳定期为 1 年。 其DMSO 或蒸馏水中的溶液可在 -20°C 下保存长达 3 个月。 |
CAS 数据库 | 127243-85-0(CAS DataBase Reference) |
IC50: 48 nM (protein kinase A)
H-89 inhibits protein kinase A, in competitive fashion against ATP. H-89 causes a dose-dependent inhibition of the forskolin-induced protein phosphorylation, with no decrease in intracellular cyclic AMP levels in PC12D cells. H-89 significantly inhibits the forskolin-induced neurite outgrowth from PC12D cells. H-89 (30 μM) inhibits significantly cAMP-dependent histone IIb phosphorylation activity in PC12D cell lysates. H-89 (1-2 μM) significantly slows the repriming rate in rat skinned fibres, most likely due to it deleteriously affecting the T-system potential. H-89 (10-100 μM) inhibits net Ca 2+ uptake by the SR and affectes the Ca 32 -sensitivity of the contractile apparatus in rat skinned fibres.
H-89 (0.2 mg/100g, i.p.) significantly increases seizure latency and threshold in PTZ-treated animals. H-89 (0.05, 0.2 mg/100 g, i.p.) prevents the epileptogenic activity of bucladesine (300 nM) with significant increase of seizure latency and seizure threshold.
安全信息
安全说明 | 22-24/25 |
---|---|
WGK Germany | 3 |
海关编码 | 29350090 |
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/11/08 | HY-15979A | H-89 dihydrochloride | 5 mg | 385元 | |
2024/11/08 | HY-15979A | N-[2-[P-溴苯丙烯盐基氨基]乙基]-5-异喹啉磺酰胺 H-89 dihydrochloride | 127243-85-0 | 10mg | 606元 |